معرفی
Dr. Elaine Willmore is a researcher at Newcastle University, specializing in oncology and molecular biology with a focus on chronic lymphocytic leukemia (CLL). Her work spans DNA repair mechanisms, protein kinase inhibition, and synthetic lethality strategies for cancer therapy.
Recent research explores:
- Targeting MDM2-p53 interactions with novel inhibitors like siremadlin
- Homologous recombination repair deficiency via ATR/CHK1/WEE1 inhibition
- Epigenetic changes in CLL, including retrotransposon methylation
- NF-κB signaling dynamics and resistance mechanisms
- DNA-PK as a therapeutic target in hematologic malignancies
Her publications highlight collaborations with the Institute of Cellular Medicine and Cancer Research UK Newcastle Innovation Lab, emphasizing translational approaches. Key contributions include studies on PARP inhibitors, DNA-PK modulation, and drug combinations to overcome chemoresistance in CLL and prostate cancer.
۰مقاله منتشرشده